FDA Oncology Announcements

GnRH antagonist × Genitourinary × Clear all

3 Announcements

FDA approves relugolix for advanced prostate cancer

Trial: HERO
Drug: ORGOVYX (relugolix) · GnRH antagonist
Condition: Genitourinary

FDA approves relugolix for advanced prostate cancer

Trial: HERO
Drug: ORGOVYX (relugolix) · GnRH antagonist
Condition: Genitourinary

Degarelix

Drug: degarelix · GnRH antagonist
Condition: Genitourinary